UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 8, 2008
Protalix BioTherapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Florida | 000-27836 | 65-0643773 | ||
| (State or other | (Commission | (IRS Employer | ||
| jurisdiction of | File Number) | Identification No.) | ||
| incorporation) |
2 Snunit Street
Science Park
POB 455
Carmiel, Israel 20100
Science Park
POB 455
Carmiel, Israel 20100
(Address of principal executive offices) (Zip Code)
(Former Name or Former Address, if Changed Since Last Report)
Registrant’s telephone number, including area code: +972-4-988-9488
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events
On September 8, 2008, Protalix BioTherapeutics, Inc. (the “Company”), issued a press release
announcing that its board of directors has set the close of business on October 2, 2008, as the
record date for shareholders entitled to receive notice of, and to vote at, the Company’s 2008
Annual Meeting of Shareholders. The meeting will be held on November 9, 2008, in Tel Aviv, Israel.
A copy of the press release dated September 8, 2008, is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| 99.1 | Press release dated September 8, 2008, titled “Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders.” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROTALIX BIOTHERAPEUTICS, INC. |
||||
| Date: September 8, 2008 | By: | /s/ David Aviezer | ||
| Name: | David Aviezer, Ph.D. | |||
| Title: | President and Chief Executive Officer | |||
3
Exhibit 99.1
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
CARMIEL, Israel — September 8, 2008 — Protalix BioTherapeutics, Inc. (Amex: PLX), today announced
that its board of directors has set the close of business on October 2, 2008, as the record date
for shareholders entitled to receive notice of, and to vote at, the Company’s 2008 Annual Meeting
of Shareholders. It is currently anticipated that the Company’s 2008 Annual Meeting of
Shareholders will be held on November 9, 2008, in Tel Aviv, Israel.
The Company plans to file with the Securities and Exchange Commission (the “SEC”), and mail to its
shareholders a proxy statement in connection with the 2008 Annual Meeting of Shareholders, and
advises its shareholders to read the proxy statement relating to the 2008 Annual Meeting of
Shareholders when it becomes available, as it will contain important information. Shareholders may
obtain a free copy of the proxy statement and any other relevant documents (when available) that
the Company files with the SEC via the SEC’s web site at www.sec.gov. The proxy statement and
these other documents, when available, may also be obtained free of charge from the Company by
directing a request to the Company at 2 Snunit Street, Science Park, POB 455, Carmiel, Israel
20100, Attention: Secretary.
The Company, its directors and named executive officers may be deemed to be participants in the
solicitation of the Company’s shareholders in connection with the 2008 Annual Meeting of
Shareholders. Shareholders may obtain information regarding the names, affiliations and interests
of such individuals in the Company’s Annual Report on Form 10-K for the year ended December 31,
2007, as amended, and in the other filings by the Company with the SEC.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated
biopharmaceutical company focused on the development and commercialization of proprietary
recombinant therapeutic proteins to be expressed through its proprietary plant cell based
expression system. Protalix’s ProCellEx™ presents a proprietary method for the expression of
recombinant proteins that Protalix believes is safe and scalable and will allow for the
cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is
enrolling and treating patients in its pivotal phase III clinical trial in Israel, Europe the
United States and other locations for its lead product candidate, prGCD, for its enzyme replacement
therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement
with the United States Food and Drug Administration on the final design of the pivotal phase III
clinical trial through the FDA’s Special Protocol Assessment (SPA) process. Protalix is also
advancing additional recombinant biopharmaceutical drug development programs.
For additional information, contact Protalix BioTherapeutics at:
investors@protalix.com
investors@protalix.com
Contact:
Marcy Strickler
The Trout Group, LLC
Telephone: 646-378-2927
Email: mstrickler@troutgroup.com
Marcy Strickler
The Trout Group, LLC
Telephone: 646-378-2927
Email: mstrickler@troutgroup.com